-
1 Comment
GlycoMimetics, Inc is currently in a long term downtrend where the price is trading 34.6% below its 200 day moving average.
From a valuation standpoint, the stock is 99.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 13.4.
GlycoMimetics, Inc's total revenue rose by inf% to $163K since the same quarter in the previous year.
Its net income has dropped by 5.7% to $-16M since the same quarter in the previous year.
Finally, its free cash flow grew by 24.1% to $-10M since the same quarter in the previous year.
Based on the above factors, GlycoMimetics, Inc gets an overall score of 3/5.
| Exchange | F |
|---|---|
| CurrencyCode | EUR |
| Sector | Healthcare |
| Industry | Biotechnology |
| ISIN | US38000Q1022 |
| Beta | 1.7 |
|---|---|
| Market Cap | 14M |
| PE Ratio | None |
| Target Price | 10.67 |
| Dividend Yield | None |
GlycoMimetics, Inc. engages in the discovery and development of therapies for cancers and inflammatory diseases in the United States. The company was founded in 2003 and is based in Monrovia, Maryland.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for GKO.F using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
